All News

Researchers indicated that these findings suggest, “an ENE detection biomarker based on TP53 mutation detection would represent an enormous clinical benefit.”

With regard to the COVID-19 pandemic, researchers recommended that resection should occur as soon as possible depending on the availability of hospital resources and local disease burden.

A restrospective study published in JAMA Dermatology found that integrating dermatologic care into oncology practices might be associated with an increased adherence to evidence-based prophylaxis for EGFRi-associated rash.

The tool was developed “with the objective of providing transparency and facilitating surgical prioritization for treatment providers.”

This study found that abdominal or pelvic radiotherapy was associated with body composition changes that can adversely influence metabolic outcomes and performance status in survivors of abdominal or pelvic tumors.

Results from this trial observed in patients with RET-altered lung and thyroid cancers also led to the approval of selpercatinib by the FDA in May for this indication.

Researchers from Singapore discussed their own experiences and strategies used to safely manage breast cancer during the COVID-19 pandemic.

A phase 1b/2a study of the combination in patients with metastatic castration resistant prostate cancer demonstrated acceptable tolerability and potential efficacy.

A study published in Cancer found that the introduction of generic aromatase inhibitors reduced the decrease trend of adherence to hormonal therapy for patients with breast cancer.

Researchers found that transoral robotic surgery “seems safe and effective compared to what’s been the standard of care for many years” for patients with early-stage oropharyngeal squamous cell carcinoma.

The FDA approved the FoundationOne Liquid CDx based on analytical and clinical validation studies that included more than 7500 samples and 30,000 unique variants across over 30 cancer types.

The updated guidelines now include tafasitamab-cxix in combination with lenalidomide with a category 2A designation as an option for the treatment of previously-treated adult patients with relapsed or refractory DLBCL not otherwise specified.

The recommendations were developed on the basis of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) ranking for genomic alterations occurring in the 8 cancers responsible for the most deaths worldwide.

The study is evaluating asciminib in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with 2 or more tyrosine-kinase inhibitors.

The new drug application was based on results from the pivotal ongoing, single-arm, phase 2 VISION study evaluating tepotinib monotherapy in patients with advanced NSCLC with METex14 skipping alterations.

The chief executive officer and co-founder of TrialJectory spoke about the online tool and what it offers for patients, providers, and pharmaceutical companies.

The study is evaluating enasidenib (Idhifa) plus best supportive care versus conventional care regimens in patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation.

The FDA approved a generic form of pemetrexed for injection as a single-agent in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not progressed after 4 cycles of first-line platinum-based chemotherapy.

The application was based on results observed in the pivotal, phase 3 CheckMate-9ER trial evaluating cabozantinib in combination with nivolumab compared with sunitinib in previously untreated patients with advanced or metastatic RCC.

These study findings suggest that the response rate to immune checkpoint blockade may be dependent on the strength of immune selection occurring early in tumorigenesis.

The director of special projects at the Union for International Cancer Control spoke about the strategy released by the World Health Organization and what needs to occur to achieve the goals laid out by the organization.

The study evaluated the efficacy and safety of IV rigosertib in patients with high-risk MDS who had progressed on, failed to respond to, or relapsed after previous treatment with an HMA within 9 cycles over the course of 1 year after initiation of HMA treatment.

The study was evaluating spartalizumab in combination with dabrafenib and trametinib among untreated patients with stage IIIC or stage IV BRAFV600 mutation-positive cutaneous melanoma.

Researchers suggested that these findings support a change of the current screening guidelines for this specific risk group and support MRI screening.

Researchers indicated that “these results reinforce the idea that there can be biological differences in prostate cancers between different ancestral groups.”

Researchers indicated that these study findings could set a basis to pinpoint independent prognostic factors related to a treatment modality in patients with breast cancer and provide clarity for the assessment of surrogate markers for overall survival.

The FDA recently announced updates to the adverse event-related data pertaining to breast implant illness and breast implant-associated anaplastic large cell lymphoma.

A survey of breast cancer survivors in the US showed that “patients were universally affected by COVID in terms of delays in breast cancer care.”

According to researchers, mindfulness-based intervention may have a positive effect on subjective measures of cognitive impairment in breast cancer survivors.

The FDA approved daratumumab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy.